THR-687 dose level 1

DRUG2 trials

Sponsors

ThromboGenics, Oxurion

Conditions

Diabetes MellitusDiabetic Macular EdemaDiabetic Retinopathy

Phase 1

A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)

CompletedNCT03666923

ThromboGenicsDiabetes Mellitus, Diabetic Macular Edema, Diabetic Retinopathy

Start: 2018-09-17End: 2019-11-20Updated: 2020-01-22

Phase 2

A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.

TerminatedNCT05063734

OxurionDiabetes Mellitus, Diabetic Macular Edema, Diabetic Retinopathy

Start: 2021-08-27End: 2022-06-29Updated: 2023-08-18